Euro-celtique S.a.

Purdue Pharma L.p.

Mark Alfonso

Benjamin Oshlack

Kirti H Valia

Ihor Shevchuk

Lino Tavares

Geraldine Marcenyac

Richard S Sackler

Paul D Goldenheim

Seth Levy

Ronald Greenbaum

Stephan Howard

Lane Gerhlein

A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.

Loratadine transdermal device and methods

A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.

Terazosin transdermal device and methods

A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.

Felodipine transdermal device and methods

A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.

Formulation for respiratory tract administration

Formulation for intranasal administration

Growing community of inventors

Easton, CT, United States of America

Mark Alfonso